To evaluate further the influence of GSDMB expression on the clinical response, a series of 138 breast cases treated with adjuvant therapy were analysed, 53 (41.1%) of these tumours were classified as HER2-positive and were treated following standard adjuvant schedules (Supplementary Table 4). The gene discussed is GSDMB; the disease is neoplasm.